BofA Securities and Citigroup served as co-lead underwriters for an offering involving Ligand Pharmaceuticals on August 22, 2025.
2 reports, 1 independent
Updated Aug 22
Gone quiet
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
BofA Securities and Citigroup served as co-lead underwriters for an offering involving Ligand Pharmaceuticals on August 22, 2025.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Ligand Pharmaceuticals
biopharmaceutical company based out of La Jolla, California
-
Citigroup
American investment bank and financial services corporation
Related events
Coverage
Newest first; wire copies grouped- Simply Wall St.A Fresh Look at Ligand Pharmaceuticals (LGND) Valuation Following $400 Million Convertible Note Offering and Capital Structure Shift If you have been watching Ligand Pharmaceuticals (LGND), the $400
- Simply Wall St.Ligand Pharmaceuticals Among 3 Stocks Possibly Trading Below Intrinsic Value Estimates As the Nasdaq reaches record highs driven by surges in chip stocks and Apple, while the S&P 500 shows signs of l